The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

NCT ID: NCT02130973

Last Updated: 2017-08-31

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2018-08-31

Brief Summary

This is a three-year study to evaluate the effect of sequential therapy of Forteo (teriparatide) and denosumab on bone density at the spine, hip, leg and forearm.

Detailed Description

In order to maximize the early anabolic effect with teriparatide (TPTD), and to avoid the development of tachyphylaxis to the continued daily administration of TPTD beyond 6 months, cyclic therapy might be optimal. Since Denosumab (Prolia) is a potent antiresorptive agent with a rapid off-effect, it might be the optimal agent to help maximize bone gains with cyclic TPTD/antiresorptive therapy. Our primary hypothesis is that the increment in bone density of the spine by DXA will be greater in women randomized to receive the cyclic sequential regimen (three separate 6 month cycles of daily subcutaneous TPTD, each followed by one subcutaneous injection of Denosumab) compared with daily sequential therapy (18 months of daily subcutaneous TPTD followed by Denosumab therapy for 18 months).

Conditions

Osteoporosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard Clinical Practice Regimen

Standard Clinical Practice (Daily) Regimen: 18 months of daily subcutaneous Forteo followed by denosumab therapy for 18 months (18 months of Forteo then 3 injections of Prolia at 18, 24 and 30 months).

Group Type: ACTIVE_COMPARATOR

Standard Clinical Practice Regimen

Intervention Type: DRUG

Standard Clinical Practice Regimen

Experimental (cyclic) regimen

Experimental (Cyclic) Regimen: three separate 6-month cycles of daily subcutaneous Forteo, each followed by one subcutaneous injection of Prolia (Forteo from 0 to 6 months, and then from 12 to 18 months and then from 24 to 30 months, for a total dose of 18 months; 3 injections of Prolia at 6, 18 and 30 months).

Group Type: EXPERIMENTAL

Experimental Cyclic Regimen

Intervention Type: DRUG

Experimental Cyclic Regimen

Interventions

Standard Clinical Practice Regimen

Standard Clinical Practice Regimen

Intervention Type: DRUG

Experimental Cyclic Regimen

Experimental Cyclic Regimen

Intervention Type: DRUG

Other Intervention Names

18 months Forteo followed by 18 months Prolia; three separate 6 month cycles of daily Forteo, each followed by one of Prolia

Eligibility Criteria

Inclusion Criteria

Subjects who meet initial pre-screening criteria will present for an on site screening visit and have a full medical history, brief physical exam, BMD and lab evaluation to confirm eligibility. Osteoporosis will be defined by DXA BMD T-Score < -2.5 at lumbar spine (at least 2 evaluable vertebrae between L1 and L4), or total hip or femoral neck. In addition, women with confirmed vertebral deformity on radiograph or lateral DXA image, or prior osteoporosis-related fracture at age >45 along with a DXA BMD T-Score < -1.5 at one or more skeletal sites will be eligible to participate.

Exclusion Criteria

• The use of drugs known to affect skeletal or calcium homeostasis.
• Multiple vertebral fractures or severe lumbar degenerative changes with fewer than 2 evaluable lumbar vertebrae
• Current use of anti-resorptive medicines

• Use of Hormone/Estrogen Therapy, raloxifene or calcitonin within the past 3 months
• Use of oral bisphosphonate for more than 4 months within the past 2 years or more than 5 years total cumulative bisphosphonate use in the past 10 years
• Use of intravenous ibandronate within the past 18 months
• Use of intravenous zoledronic acid within the past 4 years
• A history of a symptomatic renal stone within the past 3 years or history of multiple symptomatic renal stones
• Skeletal Disorders other than osteoporosis including: Hypercalcemia, hyperparathyroidism, Paget's Disease or osteomalacia
• Untreated or uncontrolled thyroid disease
• Elevated Bone Specific Alkaline Phosphatase level
• History of external or internal radiation therapy
• Renal insufficiency with estimated GFR below 30 ml/min
• Liver function tests (ALT/AST) more than 1.5 times the upper limit of normal
• Clinically significant hyperuricemia or active gout
• Any contraindications to receipt of Teriparatide or Denosumab (including hypocalcemia)
• History of an atypical fracture of the femoral shaft

• Minimum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Health Research, Inc.

OTHER

Sponsor Role: lead

Responsible Party

Felicia Cosman, M.D.

Professor of Clinical Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Felicia Cosman, M.D.

Role: PRINCIPAL_INVESTIGATOR

Helen Hayes Hospital

Locations

Helen Hayes Hospital

West Haverstraw, New York, United States

Countries

United States

References

Cosman F, McMahon D, Dempster D, Nieves JW. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. J Bone Miner Res. 2020 Feb;35(2):219-225. doi: 10.1002/jbmr.3850. Epub 2019 Oct 23.

Reference Type: DERIVED

PMID: 31419313 (View on PubMed)

Other Identifiers

AMG 10-05

Identifier Type: -

Identifier Source: org_study_id